1003 related articles for article (PubMed ID: 33782830)
1. Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of Remdesivir, a SARS-CoV-2 Replication Inhibitor.
Humeniuk R; Mathias A; Kirby BJ; Lutz JD; Cao H; Osinusi A; Babusis D; Porter D; Wei X; Ling J; Reddy YS; German P
Clin Pharmacokinet; 2021 May; 60(5):569-583. PubMed ID: 33782830
[TBL] [Abstract][Full Text] [Related]
2. Safety, Tolerability, and Pharmacokinetics of Remdesivir, An Antiviral for Treatment of COVID-19, in Healthy Subjects.
Humeniuk R; Mathias A; Cao H; Osinusi A; Shen G; Chng E; Ling J; Vu A; German P
Clin Transl Sci; 2020 Sep; 13(5):896-906. PubMed ID: 32589775
[TBL] [Abstract][Full Text] [Related]
3. Simulation of Remdesivir Pharmacokinetics and Its Drug Interactions.
Deb S; Reeves AA
J Pharm Pharm Sci; 2021; 24():277-291. PubMed ID: 34107241
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and tissue distribution of remdesivir and its metabolites nucleotide monophosphate, nucleotide triphosphate, and nucleoside in mice.
Hu WJ; Chang L; Yang Y; Wang X; Xie YC; Shen JS; Tan B; Liu J
Acta Pharmacol Sin; 2021 Jul; 42(7):1195-1200. PubMed ID: 33041326
[TBL] [Abstract][Full Text] [Related]
5. Hybrid physiologically-based pharmacokinetic model for remdesivir: Application to SARS-CoV-2.
Gallo JM
Clin Transl Sci; 2021 May; 14(3):1082-1091. PubMed ID: 33404204
[TBL] [Abstract][Full Text] [Related]
6. Off-Target
Xu Y; Barauskas O; Kim C; Babusis D; Murakami E; Kornyeyev D; Lee G; Stepan G; Perron M; Bannister R; Schultz BE; Sakowicz R; Porter D; Cihlar T; Feng JY
Antimicrob Agents Chemother; 2021 Jan; 65(2):. PubMed ID: 33229429
[TBL] [Abstract][Full Text] [Related]
7. Physiologically-Based Pharmacokinetic Modeling of Remdesivir and Its Metabolites to Support Dose Selection for the Treatment of Pediatric Patients With COVID-19.
Lutz JD; Mathias A; German P; Pikora C; Reddy S; Kirby BJ
Clin Pharmacol Ther; 2021 Apr; 109(4):1116-1124. PubMed ID: 33501997
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of remdesivir and GS-441524 in two critically ill patients who recovered from COVID-19.
Tempestilli M; Caputi P; Avataneo V; Notari S; Forini O; Scorzolini L; Marchioni L; Ascoli Bartoli T; Castilletti C; Lalle E; Capobianchi MR; Nicastri E; D'Avolio A; Ippolito G; Agrati C;
J Antimicrob Chemother; 2020 Oct; 75(10):2977-2980. PubMed ID: 32607555
[TBL] [Abstract][Full Text] [Related]
9. Remdesivir and GS-441524 Retain Antiviral Activity against Delta, Omicron, and Other Emergent SARS-CoV-2 Variants.
Pitts J; Li J; Perry JK; Du Pont V; Riola N; Rodriguez L; Lu X; Kurhade C; Xie X; Camus G; Manhas S; Martin R; Shi PY; Cihlar T; Porter DP; Mo H; Maiorova E; Bilello JP
Antimicrob Agents Chemother; 2022 Jun; 66(6):e0022222. PubMed ID: 35532238
[TBL] [Abstract][Full Text] [Related]
10. Role of OATP4C1 in Renal Handling of Remdesivir and its Nucleoside Analog GS-441524: The First Approved Drug for Patients with COVID-19.
Sato T; Maekawa M; Mano N; Abe T; Yamaguchi H
J Pharm Pharm Sci; 2021; 24():227-236. PubMed ID: 34048668
[TBL] [Abstract][Full Text] [Related]
11. A mechanism-based pharmacokinetic model of remdesivir leveraging interspecies scaling to simulate COVID-19 treatment in humans.
Hanafin PO; Jermain B; Hickey AJ; Kabanov AV; Kashuba AD; Sheahan TP; Rao GG
CPT Pharmacometrics Syst Pharmacol; 2021 Feb; 10(2):89-99. PubMed ID: 33296558
[TBL] [Abstract][Full Text] [Related]
12. Real-life study on the pharmacokinetic of remdesivir in ICU patients admitted for severe COVID-19 pneumonia.
Corcione S; De Nicolò A; Montrucchio G; Scabini S; Avataneo V; Bonetto C; Mornese Pinna S; Cusato J; Canta F; Urbino R; Di Perri G; Brazzi L; De Rosa FG; D'Avolio A
Br J Clin Pharmacol; 2021 Dec; 87(12):4861-4867. PubMed ID: 33990984
[TBL] [Abstract][Full Text] [Related]
13. Remdesivir: Review of Pharmacology, Pre-clinical Data, and Emerging Clinical Experience for COVID-19.
Jorgensen SCJ; Kebriaei R; Dresser LD
Pharmacotherapy; 2020 Jul; 40(7):659-671. PubMed ID: 32446287
[TBL] [Abstract][Full Text] [Related]
14. Intravenous delivery of GS-441524 is efficacious in the African green monkey model of SARS-CoV-2 infection.
Pitts J; Babusis D; Vermillion MS; Subramanian R; Barrett K; Lye D; Ma B; Zhao X; Riola N; Xie X; Kajon A; Lu X; Bannister R; Shi PY; Toteva M; Porter DP; Smith BJ; Cihlar T; Mackman R; Bilello JP
Antiviral Res; 2022 Jul; 203():105329. PubMed ID: 35525335
[TBL] [Abstract][Full Text] [Related]
15. A Review on Remdesivir: A Possible Promising Agent for the Treatment of COVID-19.
Hashemian SM; Farhadi T; Velayati AA
Drug Des Devel Ther; 2020; 14():3215-3222. PubMed ID: 32821086
[TBL] [Abstract][Full Text] [Related]
16. Key Metabolic Enzymes Involved in Remdesivir Activation in Human Lung Cells.
Li R; Liclican A; Xu Y; Pitts J; Niu C; Zhang J; Kim C; Zhao X; Soohoo D; Babusis D; Yue Q; Ma B; Murray BP; Subramanian R; Xie X; Zou J; Bilello JP; Li L; Schultz BE; Sakowicz R; Smith BJ; Shi PY; Murakami E; Feng JY
Antimicrob Agents Chemother; 2021 Aug; 65(9):e0060221. PubMed ID: 34125594
[TBL] [Abstract][Full Text] [Related]
17. A Review on Remdesivir: A Broad-spectrum Antiviral Molecule for Possible COVID-19 Treatment.
Khazir J; Maqbool T; Mir BA
Mini Rev Med Chem; 2021; 21(17):2530-2543. PubMed ID: 33596800
[TBL] [Abstract][Full Text] [Related]
18. Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency.
Gordon CJ; Tchesnokov EP; Woolner E; Perry JK; Feng JY; Porter DP; Götte M
J Biol Chem; 2020 May; 295(20):6785-6797. PubMed ID: 32284326
[TBL] [Abstract][Full Text] [Related]
19. Remdesivir (GS-5734) in COVID-19 Therapy: The Fourth Chance.
Moirangthem DS; Surbala L
Curr Drug Targets; 2021; 22(12):1346-1356. PubMed ID: 33267759
[TBL] [Abstract][Full Text] [Related]
20. Rethinking Remdesivir: Synthesis, Antiviral Activity, and Pharmacokinetics of Oral Lipid Prodrugs.
Schooley RT; Carlin AF; Beadle JR; Valiaeva N; Zhang XQ; Clark AE; McMillan RE; Leibel SL; McVicar RN; Xie J; Garretson AF; Smith VI; Murphy J; Hostetler KY
Antimicrob Agents Chemother; 2021 Sep; 65(10):e0115521. PubMed ID: 34310217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
